AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event ... Bioepsis were first to launch biosimilar Hadlima (adalimumab-bwwd) that day, at the sale price ...

The South Korean drugmaker added that Hyrimoz and Hadlima, Humira biosimilars marketed by CVS Health (CVS)/Sandoz (SDXNY) ...

of Humira. Most are, however, working to get interchangeable status for their biosimilars, and three of them – Organon/Samsung Bioepis’ Hadlima, Sandoz’ Hyrimoz, and Celltrion’s Yuflyma ...

The copycat drug called Hadlima will be listed at US$1,038 (RM4,846) per month, representing an 85% discount of Humira’s current US$6,922 (RM32,315) monthly price, the companies said.